|Table of Contents|

Efficacy of LncRNA SNHG14 combined with Fk506-9 protein in predicting long-term poor prognosis after MAP neoadjuvant chemotherapy for small round cell osteosarcoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 06
Page:
995-1001
Research Field:
Publishing date:

Info

Title:
Efficacy of LncRNA SNHG14 combined with Fk506-9 protein in predicting long-term poor prognosis after MAP neoadjuvant chemotherapy for small round cell osteosarcoma
Author(s):
JI Xiaofei1; DONG Li1; GE Jiejie1; FANG Panpan2
1.Laboratory Department of Zhengzhou Universitry Central Hospital,Henan Zhengzhou 450007,China；2.Key Laboratory of Children's Infection and Immunity,Zhengzhou Children's Hospital/the Affiliated Children's Hospital of Zhengzhou University,Henan Zhengzhou 4
Keywords:
small round cell osteosarcoma; LncRNA SNHG14; Fk506-9 protein; new adjuvant chemotherapy; children; poor prognosis; diagnostic evaluation
PACS:
R738.1
DOI:
10.3969/j.issn.1672-4992.2025.06.016
Abstract:
Objective:To evaluate the diagnostic efficacy of LncRNA SNHG14 combined with Fk506-9 protein in the long-term poor prognosis of children with small round cell osteosarcoma (SROS) after neoadjuvant chemotherapy with high-dose methotrexate,doxorubicin,and cisplatin (MAP).Methods:Children with small round cell osteosarcoma who received MAP neoadjuvant chemotherapy in our hospital from April 2021 to April 2022 were enrolled in this prospective cohort study.According to the presence or absence of poor prognosis at the end of 2-year follow-up,they were divided into bad prognosis group (BG group) and good prognosis group (GG group).Serum LncRNA SNHG14 and Fk506-9 protein concentrations were collected at baseline and within 2 hours after initial MAP neoadjuvant chemotherapy.Followed up for 2 years,with a deadline of March 30,2024.Descriptive statistics were used to describe the baseline characteristics of each group,and t-test,χ2-test,analysis of variance and other methods were used to compare the baseline indicators and LncRNA SNHG14 and Fk506-9 protein concentrations between different groups.After adjusting the baseline confounding variables,binary and multi-factor Logistics regression analysis was used to screen the risk factors affecting the outcome of adverse prognosis,and receiver curve ROC was used to analyze the actual efficacy of the prediction model for the diagnosis of adverse prognosis.Results:A total of 69 children were enrolled in this study.The incidence of long-term poor prognosis was 69.57%.Age (years old),BMI (kg/m2),red blood cell count (×1012/L),hemoglobin (g/dL),immunoglobulin (g/L),the level of complement (C3,g/L),LncRNA SNHG14,Fk506-9 protein (ng/L),maximum tumor diameter (cm),and ECOG score (scores) were the main risk factors for long-term poor prognosis in children with SROS after MAP neoadjuvant chemotherapy (P＜0.05).The AUC (95%CI) of LncRNA SNHG14 combined with Fk506-9 protein in the combined diagnosis was 0.948［0.901~0.996］.The sensitivity was 0.952.The specificity was 0.875.The accuracy was 0.899,and the Youden's index was 0.827.Conclusion:LncRNA SNHG14 joint Fk506-9 protein can effectively predict long-term adverse outcomes after MAP neoadjuvant chemotherapy in children with small round cell osteosarcoma,and the prediction model has better diagnostic value.

References:

［1］ SBARAGLIA M,RIGHI A,GAMBAROTTI M,et al.Ewing sarcoma and Ewing-like tumors ［J］.Virchows Arch,2020,476(1):109-119.
[2] AYKAN MB,ERTURK I,ACAR R,et al.High-dose chemotherapy response in adults with relapsed/refractory small round cell tumours ［J］.J Coll Physicians Surg Pak,2022,32(1):51-56.
[3] TIPPETT VL,TATTERSALL L,AB LATIF NB,et al.The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma:a systematic review ［J］.Oncogene,2023,42(4):259-277.
[4] TSUDA Y,TSOI K,PARRY MC,et al.Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma ［J］.Bone Joint J,2020,102-b(6):795-803.
[5] KOVACS SK,MANASSAPORN A,NIELSEN GP,et al.Molecular and immunohistochemical testing of bone tumours:review and update ［J］.Histopathology,2023,82(6):794-811.
[6] TRUONG DD,LAMHAMEDI-CHERRADI SE,PORTER RW,et al.Dissociation protocols used for sarcoma tissues bias the transcriptome observed in single-cell and single-nucleus RNA sequencing ［J］.BMC Cancer,2023,23(1):488.
[7] HIEMCKE-JIWA LS,SUMATHI VP,BAUMHOER D,et al.Small cell osteosarcoma versus fusion-driven round cell sarcomas of bone:retrospective clinical,radiological,pathological,and (epi)genetic comparison with clinical implications ［J］.Virchows Arch,2024,484(3):451-463.
[8] SHOAIB Z,FAN TM,IRUDAYARAJ JMK.Osteosarcoma mechanobiology and therapeutic targets ［J］.Br J Pharmacol,2022,179(2):201-217.
[9] CERSOSIMO F,LONARDI S,BERNARDINI G,et al.Tumor-associated macrophages in osteosarcoma:from mechanisms to therapy ［J］.Int J Mol Sci,2020,21(15):5207.
[10] YANG C,TIAN Y,ZHAO F,et al.Bone microenvironment and osteosarcoma metastasis ［J］.Int J Mol Sci,2020,21(19):6985.
[11] 中国医师协会骨科医师分会骨肿瘤专业委员会,郭卫,牛晓辉,等.骨肉瘤临床循证诊疗指南［J］.中华骨与关节外科杂志,2018,11(4):288-301. Bone Tumor Committee of Orthopaedic Branch,Chinese Medical Doctor Association,GUO W,NIU XH,et al.Clinical evidence-based guidelines for osteosarcoma management ［J］.Chin J Bone Joint Surg，2018，11(4):288-301.
[12] SOBIC SARANOVIC DP,NIKITOVIC M,SAPONJSKI J,et al.Post-treatment FDG PET/CT predicts progression-free survival in young patients with small round blue cell tumors:Ewing sarcoma and PNET［J］.Eur J Radiol,2020,129:109076.
[13] YIN T,SHAO M,SUN M,et al.Gastrointestinal Ewing sarcoma:A clinicopathological and molecular genetic analysis of 25 cases［J］.Am J Surg Pathol,2024,48(3):275-283.
[14] ISMAIL MD,WIRATNAYA IGE,RADITYA RH.Evaluating the outcome and patient safety of methotrexate,doxorubicin,and cisplatin regimen for chemotherapy in osteosarcoma:A Meta-analysis ［J］.Asian Pac J Cancer Prev,2024,25(5):1497-1505.
[15] PAPAKONSTANTINOU E,STAMATOPOULOS A,ATHANASIADIS DI,et al.Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy.A systematic review and meta-analysis ［J］.J Bone Oncol,2020,25:100319.
[16] 李少利,董颖,袁瑛.2023年第2版《NCCN恶性骨肿瘤临床实践指南》更新解读［J］.实用肿瘤杂志,2023,38(1):1-4. LI SL,DONG Y,YUAN Y.Updates to version 2.2023 NCCN clinical practice guidelines for malignant bone tumors:an expert interpretation［J］.J Pract Oncol,2023,38(1):1-4.
[17] 甘凤娇，胡康，李艳，等.长链非编码RNA在乳腺癌中的研究进展［J］.现代肿瘤医学，2020，28（23）：4193-4196. GAN Fengjiao，HU Kang，LI Yan，et al.Research progress of long non-coding RNA in breast cancer［J］.Modern Oncology,2020，28（23）：4193-4196.
[18] 包晗，苏洪英.长链非编码RNA作为肝癌血清肿瘤标志物的研究进展［J］.现代肿瘤医学，2021,29(13):2355-2358. BAO Han,SU Hongying.Research progress of lncRNA acting as novel sera biomarkers for hepatocellular carcinoma［J］.Modern Oncology,2021,29(13):2355-2358.
[19] FU CY,LAY IS,SHIBU MA,et al.Selective activation of ZAK β expression by 3-hydroxy-2-phenylchromone inhibits human osteosarcoma cells and triggers apoptosis via JNK activation ［J］.Int J Mol Sci,2020,21(9):3366.
[20] HOU XK,MAO JS.Long noncoding RNA SNHG14 promotes osteosarcoma progression via miR-433-3p/FBXO22 axis ［J］.Biochem Biophys Res Commun,2020,523(3):766-772.
[21] LI L,ZHANG Y,GAO Y,et al.LncSNHG14 promotes nutlin3a resistance by inhibiting ferroptosis via the miR-206/SLC7A11 axis in osteosarcoma cells ［J］.Cancer Gene Ther,2023,30(5):704-715.
[22] CHEN C,XIE L,REN T,et al.Immunotherapy for osteosarcoma:Fundamental mechanism,rationale,and recent breakthroughs ［J］.Cancer Lett,2021,500:1-10.

Memo

Memo:
河南省医学科技攻关计划项目（编号：LHGJ20220862）
Last Update: 1900-01-01